Breakthrough Antifungal Therapy Demonstrates Efficacy in Severe Valley Fever Cases

An investigational antifungal treatment, olorofim, has shown significant clinical promise for patients with refractory disseminated coccidioidomycosis (DCM), a severe form of Valley fever, according to results from an open-label phase IIb trial. Among 41 patients with DCM who had exhausted standard treatment options, 75.6% exhibited either a complete or partial clinical response after 42 days of therapy, with similar results maintained at 84 days, as reported by Fariba Donovan, MD, PhD, and colleagues from the University of Arizona’s Valley Fever Center for Excellence.

The study highlighted notable disparities in treatment outcomes based on the presence of central nervous system (CNS) involvement. Patients without CNS infections achieved an 80% clinical success rate, compared to 64.7% among those with CNS infections but no implanted devices, and 41.7% when both CNS infection and device presence were confirmed. These findings suggest that localized disease and absence of invasive devices may enhance therapeutic efficacy.

DCM, a severe complication of coccidioidomycosis caused by the inhalation of Coccidioides spores, is rare yet life-threatening, affecting approximately 1% of the 206,000 to 360,000 annual U.S. cases. Standard treatments with amphotericin B or triazole antifungals often result in incomplete resolution and require lifelong management. Olorofim, administered at a 90 mg twice-daily dose following an initial 300 mg loading dose, demonstrated potential as a salvage therapy for patients with resistant or progressive disease. The trial, which included patients aged 16 and older with inadequate response to conventional therapies, found that 73.2% of participants remained clinically stable after 84 days, with 61.5% achieving success during an extended treatment phase of over 90 days.

Despite these encouraging outcomes, challenges persist. No patients achieved a comprehensive global response combining clinical, radiologic, and mycologic improvements, and serological markers remained positive in all cases with follow-up data, even after more than a year of treatment. Researchers noted that persistent seropositivity does not necessarily indicate ongoing infection, as serologic changes can lag behind clinical improvements.

Adverse events were reported in 39% of patients (gastrointestinal), 29.3% (hepatobiliary), and 22% (musculoskeletal), with no deaths during the main treatment phase. However, the all-cause mortality rate reached 9.8% during the extended phase, with three deaths attributed to DCM. The study’s open-label design and small sample size limit definitive conclusions, but the results align favorably with existing azole therapies, particularly given the high proportion of refractory cases in the cohort.

These findings underscore olorofim’s potential to address a critical unmet need in managing severe Valley fever, offering hope for patients with otherwise limited therapeutic options.

Source link